Key facts
- Clotprotect’s last known valuation is $6.6M (Feb 2025).
- It has raised $2.5M; the latest was Early Stage VC ($1.4M) in Feb 2026.
- Notable investors include Innovate UK, Lifted Ventures, O2h Ventures, Science Entrepreneur Club, University of Leeds.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Clotprotect
- ·The full record, as it builds
Funding rounds
No funding rounds for Clotprotect are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Clotprotect
Developer of a molecule direct plasmin inhibitor intended to improve the treatment of severe bleeding. The company's platform offers a therapy aiming to enhance efficacy compared to tranexamic acid (TXA), enabling doctors to extend treatment windows, reduce bleeding and transfusion needs, and shorten hospital stays for trauma and surgical patients.
- Sector
- Healthcare
- HQ
- Leeds, United Kingdom
- Founded
- 2024
- Employees
- 1
- Website
- clotprotect.com/
- Ownership
- Privately Held (backing)
Clotprotect doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Clotprotect shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Clotprotect in its N-PORT filings yet. We sweep new filings monthly.